Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
987 questions in 78 reviews · Haematology
current versionsNo studies 256 · 25.9%Ungraded 64 · 6.5%Very low 207 · 21%Low 247 · 25%Moderate 163 · 16.5%High 50 · 5.1%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Nivolumab vs no other intervention Response rate · adults with Hodgkin's lymphoma Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer) (2018) · Cochrane | no estimate extracted | 3 studies · 283 participants | Very low |
Nivolumab vs no other intervention Treatment‐related mortality · adults with Hodgkin's lymphoma Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer) (2018) · Cochrane | no estimate extracted | NR | No studies |
Nivolumab vs no other intervention Grade 3 or 4 AEs · adults with Hodgkin's lymphoma Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer) (2018) · Cochrane | no estimate extracted | 3 studies · 283 participants | Very low |
Nivolumab vs no other intervention SAEs · adults with Hodgkin's lymphoma Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer) (2018) · Cochrane | no estimate extracted | 1 study · 243 participants | Very low |
Prophylactic platelet transfusion prior to surgery vs no prophylactic platelet transfusion prior to surgery All‐cause mortality within 30 days of surgery · people with a low platelet count Prophylactic platelet transfusions prior to surgery for people with a low platelet count (2018) · Cochrane | RR 0.78 [0.41, 1.45] | 1 study · 72 participants | Very low |
Prophylactic platelet transfusion prior to surgery vs alternative treatments Mortality secondary to thromboembolism within 30 days of surgery – not reported · people with a low platelet count Prophylactic platelet transfusions prior to surgery for people with a low platelet count (2018) · Cochrane | no estimate extracted | NR | No studies |
Prophylactic platelet transfusion prior to surgery vs alternative treatments Mortality secondary to infection within 30 days of surgery – not reported · people with a low platelet count Prophylactic platelet transfusions prior to surgery for people with a low platelet count (2018) · Cochrane | no estimate extracted | NR | No studies |
Prophylactic platelet transfusion prior to surgery vs alternative treatments Number of participants with major bleeding within 7 days of surgery (bleeding that required ≥ 2 units of whole blood/red blood cells within 24 hours of the bleeding) · people with a low platelet count Prophylactic platelet transfusions prior to surgery for people with a low platelet count (2018) · Cochrane | no estimate extracted | 1 study · 36 participants | Very low |
Prophylactic platelet transfusion prior to surgery vs alternative treatments Number of participants with minor procedure‐related bleeding within 7 days of surgery · people with a low platelet count Prophylactic platelet transfusions prior to surgery for people with a low platelet count (2018) · Cochrane | RR 0.89 [0.06, 13.23] | 1 study · 36 participants | Very low |
Prophylactic platelet transfusion prior to surgery vs alternative treatments Serious adverse events (transfusion‐related adverse effects within 24 hours of the transfusion) · people with a low platelet count Prophylactic platelet transfusions prior to surgery for people with a low platelet count (2018) · Cochrane | RR 2.7 [0.12, 62.17] | 1 study · 36 participants | Very low |
Intervention NR All‐cause mortality within 30 days of surgery – not reported · people with a low platelet count Prophylactic platelet transfusions prior to surgery for people with a low platelet count (2018) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Mortality secondary to bleeding within 30 days of surgery – not reported · people with a low platelet count Prophylactic platelet transfusions prior to surgery for people with a low platelet count (2018) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Mortality secondary to thromboembolism within 30 days of surgery – not reported · people with a low platelet count Prophylactic platelet transfusions prior to surgery for people with a low platelet count (2018) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Mortality secondary to infection within 30 days of surgery – not reported · people with a low platelet count Prophylactic platelet transfusions prior to surgery for people with a low platelet count (2018) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Number of participants with major bleeding within 7 days of surgery · people with a low platelet count Prophylactic platelet transfusions prior to surgery for people with a low platelet count (2018) · Cochrane | no estimate extracted | 1 study · 65 participants | Very low |
Prophylactic platelet transfusion prior to surgery vs no prophylactic platelet transfusion prior to surgery Mortality secondary to bleeding within 30 days of surgery – not reported · people with a low platelet count Prophylactic platelet transfusions prior to surgery for people with a low platelet count (2018) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Number of participants with minor procedure‐related bleeding within 7 days of surgery · people with a low platelet count Prophylactic platelet transfusions prior to surgery for people with a low platelet count (2018) · Cochrane | no estimate extracted | 1 study · 65 participants | Very low |
Intervention NR Serious adverse events – not reported · people with a low platelet count Prophylactic platelet transfusions prior to surgery for people with a low platelet count (2018) · Cochrane | no estimate extracted | NR | No studies |
Prophylactic platelet transfusion prior to surgery vs no prophylactic platelet transfusion prior to surgery Mortality secondary to thromboembolism within 30 days of surgery – not reported · people with a low platelet count Prophylactic platelet transfusions prior to surgery for people with a low platelet count (2018) · Cochrane | no estimate extracted | NR | No studies |
Prophylactic platelet transfusion prior to surgery vs no prophylactic platelet transfusion prior to surgery Mortality secondary to infection within 30 days of surgery – not reported · people with a low platelet count Prophylactic platelet transfusions prior to surgery for people with a low platelet count (2018) · Cochrane | no estimate extracted | NR | No studies |
Prophylactic platelet transfusion prior to surgery vs no prophylactic platelet transfusion prior to surgery Number of participants with major bleeding within 7 days of surgery (surgical site bleeding requiring a second intervention or reoperation or surgical site bleeding that causes a haematoma or haemarthrosis of sufficient size to delay mobilisation ... · people with a low platelet count Prophylactic platelet transfusions prior to surgery for people with a low platelet count (2018) · Cochrane | RR 1.6 [0.29, 8.92] | 1 study · 64 participants | Very low |
Prophylactic platelet transfusion prior to surgery vs no prophylactic platelet transfusion prior to surgery The number of participants with minor procedure‐related bleeding within 7 days of surgery · people with a low platelet count Prophylactic platelet transfusions prior to surgery for people with a low platelet count (2018) · Cochrane | RR 1.29 [0.9, 1.85] | 1 study · 64 participants | Very low |
Prophylactic platelet transfusion prior to surgery vs no prophylactic platelet transfusion prior to surgery Serious adverse events (surgery‐related adverse effects within 30 days) · people with a low platelet count Prophylactic platelet transfusions prior to surgery for people with a low platelet count (2018) · Cochrane | no estimate extracted | 1 study · 64 participants | Very low |
Prophylactic platelet transfusion prior to surgery vs alternative treatments All‐cause mortality within 30 days of surgery – not reported · people with a low platelet count Prophylactic platelet transfusions prior to surgery for people with a low platelet count (2018) · Cochrane | no estimate extracted | NR | No studies |
Prophylactic platelet transfusion prior to surgery vs alternative treatments Mortality secondary to bleeding within 30 days of surgery – not reported · people with a low platelet count Prophylactic platelet transfusions prior to surgery for people with a low platelet count (2018) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Overall survival## · patients with multiple myeloma Bisphosphonates in multiple myeloma: an updated network meta‐analysis (2017) · Cochrane | HR 0.9 [0.76, 1.07] | 14 studies · 2706 participants | Moderate |
Intervention NR Progression‐free survival### · patients with multiple myeloma Bisphosphonates in multiple myeloma: an updated network meta‐analysis (2017) · Cochrane | HR 0.75 [0.57, 1] | 7 studies · 908 participants | Low |
Intervention NR Vertebral fractures · patients with multiple myeloma Bisphosphonates in multiple myeloma: an updated network meta‐analysis (2017) · Cochrane | RR 0.74 [0.62, 0.89] | 7 studies · 1116 participants | Moderate |
Intervention NR Non‐vertebral fractures · patients with multiple myeloma Bisphosphonates in multiple myeloma: an updated network meta‐analysis (2017) · Cochrane | RR 1.03 [0.68, 1.56] | 6 studies · 1389 participants | Moderate |
Intervention NR Skeletal‐related events · patients with multiple myeloma Bisphosphonates in multiple myeloma: an updated network meta‐analysis (2017) · Cochrane | RR 0.74 [0.63, 0.88] | 10 studies · 2141 participants | Moderate |
Intervention NR Pain · patients with multiple myeloma Bisphosphonates in multiple myeloma: an updated network meta‐analysis (2017) · Cochrane | RR 0.75 [0.6, 0.95] | 8 studies · 1281 participants | Very low |
Intervention NR Osteonecrosis of jaw · patients with multiple myeloma Bisphosphonates in multiple myeloma: an updated network meta‐analysis (2017) · Cochrane | RR 4.61 [0.99, 21.35] | 6 studies · 1284 participants | Low |
Intervention NR Mortality (calculated instead of overall survival) Chemotherapy alone versus chemotherapy plus radiotherapy for adults with early stage Hodgkin lymphoma (2017) · Cochrane | HR 0.48 [0.22, 1.06] | 5 studies · 1388 participants | Moderate |
Intervention NR Relapse, progression or death (calculated instead of PFS) sensitivity analysis ‐ without HD6trial due to high risk of other bias Chemotherapy alone versus chemotherapy plus radiotherapy for adults with early stage Hodgkin lymphoma (2017) · Cochrane | HR 0.24 [0.07, 0.88] | 900 participants | Moderate |
Intervention NR Infection‐ related mortality Chemotherapy alone versus chemotherapy plus radiotherapy for adults with early stage Hodgkin lymphoma (2017) · Cochrane | RR 6.9 [0.36, 132.34] | 1 study · 276 participants | Low |
Intervention NR Second cancer‐ related mortality Chemotherapy alone versus chemotherapy plus radiotherapy for adults with early stage Hodgkin lymphoma (2017) · Cochrane | RR 2.22 [0.7, 7.03] | 1 study · 276 participants | Low |
Intervention NR Cardiac disease‐ related mortality Chemotherapy alone versus chemotherapy plus radiotherapy for adults with early stage Hodgkin lymphoma (2017) · Cochrane | RR 0.99 [0.14, 6.9] | 1 study · 276 participants | Low |
Intervention NR Complete response rate Chemotherapy alone versus chemotherapy plus radiotherapy for adults with early stage Hodgkin lymphoma (2017) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Mortality sensitivity analysis (calculated instead of overall survival) ‐ without UK NCRI Rapid trial and MSKCC trial #90‐44due to high risk of other bias Chemotherapy alone versus chemotherapy plus radiotherapy for adults with early stage Hodgkin lymphoma (2017) · Cochrane | HR 0.31 [0.19, 0.52] | 3 studies · 816 participants | Moderate |
Intervention NR Relapse, progression or death (calculated instead of PFS) Chemotherapy alone versus chemotherapy plus radiotherapy for adults with early stage Hodgkin lymphoma (2017) · Cochrane | HR 0.42 [0.25, 0.72] | 4 studies · 1351 participants | Moderate |
Intervention NR Infection‐ related mortality Chemotherapy alone versus chemotherapy plus radiotherapy for adults with early stage Hodgkin lymphoma (2017) · Cochrane | RR 0.33 [0.01, 8.06] | 1 study · 152 participants | Low |
Intervention NR Second cancer‐ related mortality Chemotherapy alone versus chemotherapy plus radiotherapy for adults with early stage Hodgkin lymphoma (2017) · Cochrane | RR 0.53 [0.07, 4.29] | 3 studies · 1199 participants | Low |
Intervention NR Cardiac disease‐ related mortality Chemotherapy alone versus chemotherapy plus radiotherapy for adults with early stage Hodgkin lymphoma (2017) · Cochrane | RR 2.94 [0.31, 27.55] | 2 studies · 457 participants | Low |
Intervention NR Complete response rate Chemotherapy alone versus chemotherapy plus radiotherapy for adults with early stage Hodgkin lymphoma (2017) · Cochrane | RR 1.08 [0.93, 1.25] | 3 studies · 376 participants | Low |
Intervention NR Mortality (calculated instead of overall survival) Chemotherapy alone versus chemotherapy plus radiotherapy for adults with early stage Hodgkin lymphoma (2017) · Cochrane | HR 2.12 [1.03, 4.37] | 1 study · 276 participants | Low |
Intervention NR Relapse, progression or death (calculated instead of PFS) Chemotherapy alone versus chemotherapy plus radiotherapy for adults with early stage Hodgkin lymphoma (2017) · Cochrane | HR 0.42 [0.14, 1.24] | 3 studies · 1176 participants | Low |
Escalated BEACOPP vs chemotherapy including ABVD Mortality · Patients with early unfavourable or advanced stage HL Comparison of first‐line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for… (2017) · Cochrane | HR 0.74 [0.57, 0.97] | 5 studies · 3142 participants | High |
Escalated BEACOPP vs chemotherapy including ABVD Progression, relapse or death · Patients with early unfavourable or advanced stage HL Comparison of first‐line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for… (2017) · Cochrane | HR 0.54 [0.45, 0.64] | 5 studies · 3142 participants | Moderate |
Escalated BEACOPP vs chemotherapy including ABVD Adverse event: treatment‐related mortality · Patients with early unfavourable or advanced stage HL Comparison of first‐line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for… (2017) · Cochrane | RR 2.15 [0.93, 4.95] | 4 studies · 2700 participants | Low |
Escalated BEACOPP vs chemotherapy including ABVD Adverse event: secondary malignancies · Patients with early unfavourable or advanced stage HL Comparison of first‐line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for… (2017) · Cochrane | RR 1 [0.68, 1.48] | 5 studies · 3332 participants | Low |